<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01992029</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2012/13</org_study_id>
    <nct_id>NCT01992029</nct_id>
  </id_info>
  <brief_title>Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>MIRSLA</acronym>
  <official_title>Etude de l'Expression Des Micro-RNA Comme Biomarqueur Diagnostic et Pronostic Dans la Sclérose Latérale Amyotrophique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal goal is to demonstrate that a specific pattern of microRNA (miRNA) expression&#xD;
      can be correlated with the definite diagnostic of Amyotrophic Lateral Sclerosis (ALS). The&#xD;
      investigators will use biological sample (from muscle biopsy, Cerebrospinal Fluid (CSF) and&#xD;
      blood sample) collected in three control populations: definite ALS patients according to El&#xD;
      Escorial diagnostic criterion, control patients without any neurological disease having an&#xD;
      orthopedic surgery for shoulder disease, and control patient explored for peripheral&#xD;
      neuropathy and myopathy. A second goal will correlate the miRNA pattern to the severity&#xD;
      and/or progression rate of the motor neurons define as the progression rate of the&#xD;
      Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) score/year.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic Lateral Sclerosis is an adult-onset neuro degenerative disease leading to muscle&#xD;
      wasting, palsy and death due to respiratory failure within 3 to 5 years. The only effective&#xD;
      drug (Riluzole) increases the life expectancy for about three months, knowing that on&#xD;
      average, the diagnostic is given after a delay of one year in France. The identification of&#xD;
      new biomarkers for early diagnostic is therefore of fundamental importance. This could&#xD;
      improve the treatment efficacy but also give important clues about the prognostic, the rate&#xD;
      of evolution and overall help identify new targets for future therapeutics. The&#xD;
      investigators' goals are to find specific miRNA patterns expression associated to ALS in&#xD;
      humans and use those patterns as diagnostic and prognostic tools.&#xD;
&#xD;
      miRNA are non-coding small fragments of RNA that binds mRNA and can down regulate their&#xD;
      expression. In humans, around 700 miRNA have been so far identified. The role of miRNA in&#xD;
      human pathology is well established in various types of cancer, but recent works have&#xD;
      emphasize their role in neuro degenerative diseases and their expression profile can&#xD;
      considered specific for Alzheimer, Parkinson and Huntington diseases. Very few data are&#xD;
      currently available about their expression pattern in ALS. Previous studies have however&#xD;
      shown that down regulating of some miRNA in spinal cord Moto neurons can trigger an ALS-like&#xD;
      clinical phenotype. A more recent work on transgenic murine model SOD1 G93A has demonstrated&#xD;
      the role of the specific miRNA206 in regulating the re-innervation processes at the&#xD;
      neuro-muscular junction. Mi206 have the ability to promote the re-innervation process and&#xD;
      therefore to slow the disease progression.&#xD;
&#xD;
      This research aimed to study the expression of more than 700 miRNA in four different groups&#xD;
      (20 patients per group): ALS patients, normal control having a shoulder surgery during which&#xD;
      they will have a muscle (deltoid) biopsy, patients explored for peripheral neuropathy with a&#xD;
      blood sample, a lumbar puncture for CSF examination and neuro-muscular biopsy and patient&#xD;
      explored for myopathy with a blood sample, a lumbar puncture for CSF examination and a&#xD;
      muscular biopsy. The ALS group will be followed up every 4 months with ALSFRS scoring and&#xD;
      blood sample and a second CSF sample only at M12. miRNA pattern expression will be compared&#xD;
      and considered significant for a 2-fold change.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">June 17, 2014</start_date>
  <completion_date type="Actual">October 22, 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>miRNA expression</measure>
    <time_frame>At inclusion (day 0)</time_frame>
    <description>miRNA expression pattern in ALS patients compared to control patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>miRNA evolution</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>Evolution of miRNA expression level in blood and CSF of ALS patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miRNA expression pattern in different ALS patients compared to control patients predictive of the clinical phenotype and of the progression of the disease.</measure>
    <time_frame>Day 0 (inclusion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in diffusivity parameters of MRI</measure>
    <time_frame>At inclusion (Day 0) and 8 month after inclusion</time_frame>
    <description>Difference in diffusivity parameters of MRI between ALS subjects and control groups</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">5</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>ALS</condition>
  <arm_group>
    <arm_group_label>ALS Patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients suffering from neuropathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients suffering from myopathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control subjects</arm_group_label>
    <description>control patients without any neurological disease having an orthopedic surgery for shoulder disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical evaluation</intervention_name>
    <description>Clinical evaluation using MRC scale, Norris bulbar scale, ALSFRS score and respiratory evaluation ( Vital Capacity, PiMax and SNIP) at M0, M4, M8, M12</description>
    <arm_group_label>ALS Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Muscular biopsy</intervention_name>
    <description>Muscular biopsy at M0</description>
    <arm_group_label>ALS Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumbar puncture</intervention_name>
    <description>Lumbar puncture at M0 and M12</description>
    <arm_group_label>ALS Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling at M0, M4, M4, M8 and M12</description>
    <arm_group_label>ALS Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurological assessments</intervention_name>
    <description>Neurological assessments (MRC score and cognitive scales: MMS and BREF)</description>
    <arm_group_label>Control patients suffering from myopathy</arm_group_label>
    <arm_group_label>Control patients suffering from neuropathy</arm_group_label>
    <arm_group_label>Control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neuro-muscular biopsy and lumbar puncture</intervention_name>
    <description>Neuro-muscular biopsy and lumbar puncture for patients explored for peripheral neuropathy</description>
    <arm_group_label>Control patients suffering from neuropathy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Muscular biopsy</intervention_name>
    <description>Muscular biopsy for patient explored for myopathy</description>
    <arm_group_label>Control patients suffering from myopathy</arm_group_label>
    <arm_group_label>Control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood sample for qRT PCR, detection and quantification for miRNA</description>
    <arm_group_label>Control patients suffering from myopathy</arm_group_label>
    <arm_group_label>Control patients suffering from neuropathy</arm_group_label>
    <arm_group_label>Control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cervical spinal cord and brain MRI</intervention_name>
    <description>ALS patients : MRI at inclusion and Month 8 Control patients suffering from neuropathy : MRI at inclusion and Month 8 Control patients suffering from myopathy : MRI at inclusion Control subjects : MRI at inclusion</description>
    <arm_group_label>ALS Patients</arm_group_label>
    <arm_group_label>Control patients suffering from myopathy</arm_group_label>
    <arm_group_label>Control patients suffering from neuropathy</arm_group_label>
    <arm_group_label>Control subjects</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood Cerebrospinal fluid muscle&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from ALS, neuropathy, myopathy or control subjects having a shoulder&#xD;
        surgery during which they will have a muscle (deltoid) biopsy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For ALS patients:&#xD;
&#xD;
          -  Age between 45 and 70 years old&#xD;
&#xD;
          -  Patients with definite criteria of ALS according to revised El Escorial criterion&#xD;
             (1998).&#xD;
&#xD;
          -  ALS Patients with a clinical motor impairment of the limbs +/- impairment of the&#xD;
             bulbar muscles.&#xD;
&#xD;
          -  Patients with a clinical motor impairment on the deltoid muscle (MRC score&lt;5)&#xD;
&#xD;
        For control patients:&#xD;
&#xD;
          -  Age between 45 and 70 years old&#xD;
&#xD;
          -  Patients having an orthopedic surgery of the shoulder with a normal neurological&#xD;
             examination&#xD;
&#xD;
          -  Patients having a peripheral neuropathy with a motor component needing a biological&#xD;
             blood sample, a lumbar puncture for CSF examination and a neuro-muscular biopsy for&#xD;
             complete diagnostic&#xD;
&#xD;
          -  Patients having a muscular myopathy needing a biological blood sample and a deltoid&#xD;
             muscle biopsy for complete diagnostic.&#xD;
&#xD;
          -  Patients affiliated to a governmental health plan&#xD;
&#xD;
          -  Clear and loyal consent form written and signed by the patient and the investigator (&#xD;
             before any exam and at least the day of inclusion)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not eligible for a muscle biopsy (anti-coagulation, anti aggregation or blood&#xD;
             coagulation pathologies)&#xD;
&#xD;
          -  Patients not eligible for lumbar puncture (anti-coagulation, anti aggregation or blood&#xD;
             coagulation pathologies, recent spine surgery, acquired or congenital spine&#xD;
             malformation, clinical signs of intracranial hypertension, cutaneous infection at the&#xD;
             punction site).&#xD;
&#xD;
          -  ALS patient with isolated bulbar symptoms&#xD;
&#xD;
          -  Patients with a clinical syndrome of ALS-plus associating extra-pyramidal symptoms,&#xD;
             cerebellar or spino-cerebellar syndromes autonomic disorders or ocular palsy.&#xD;
&#xD;
          -  Patients with marked cognitive impairments (MMS&lt;24/30 or BREF&lt;14/18)&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Patients with any neurological or non-neurological disorders interfering with the&#xD;
             ALSFRS score&#xD;
&#xD;
          -  Patients who could not express their consent&#xD;
&#xD;
          -  Patients in emergency situation&#xD;
&#xD;
          -  Patients under guardianship or judicial protection&#xD;
&#xD;
          -  Pace maker, cochlear implant&#xD;
&#xD;
          -  Spinal cord compression or trauma&#xD;
&#xD;
          -  Spine surgery&#xD;
&#xD;
          -  Spinal deformity&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Metallic foreign body&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Vital capacity &lt; 50 %&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Cécile WIELANEK-BACHELET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodolphe THIEBAUT, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>November 2, 2018</last_update_submitted>
  <last_update_submitted_qc>November 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>miRNA</keyword>
  <keyword>biomarker</keyword>
  <keyword>monocentric observational study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

